Health and Economic Burden of Severe Respiratory Syncytial Virus Infections Among Older Adults in Japan: A Retrospective Administrative Database Study
Authors:
Open Access
- 10 November 2026
- journal article
- research article
- Published by Springer Nature in Drugs - Real World Outcomes
- p. 1-12
Abstract
No abstract availableFunding Information
- GlaxoSmithKline Biologicals
This publication has 20 references indexed in Scilit:
- Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older AdultsNew England Journal of Medicine, 2023
- First RSV vaccine approvalsThe Lancet Microbe, 2023
- Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older AdultsNew England Journal of Medicine, 2023
- Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older AdultsNew England Journal of Medicine, 2023
- Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age GroupsPharmacoEconomics, 2022
- Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection studyInfluenza and Other Respiratory Viruses, 2022
- Context and Considerations for Use of Two Japanese Real-World Databases in Japan: Medical Data Vision and Japanese Medical Data CenterDrugs - Real World Outcomes, 2022
- Occurrence and disease burden of respiratory syncytial virus and other respiratory pathogens in adults aged ≥65 years in community: A prospective cohort study in JapanInfluenza and Other Respiratory Viruses, 2021
- Epidemiology and burden of illness of seasonal influenza among the elderly in Japan: A systematic literature review and vaccine effectiveness meta‐analysisInfluenza and Other Respiratory Viruses, 2020
- Respiratory Syncytial Virus–Associated Hospitalizations Among Adults With Chronic Medical ConditionsClinical Infectious Diseases, 2020